Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.In recurrent advanced ovarian cancer, early CA-125 kinetics modeling is a pragmatic prognostic tool. A joint model with tumor size did not significantly improve prognostic accuracy over CA-125 alone for survival outcomes.
Area Of Science
- Oncology
- Pharmacokinetics
- Biomarker Analysis
Background
- Recurrent advanced ovarian cancer requires novel chemotherapy-free treatment strategies.
- Companion tests are needed to guide treatment selection and predict patient outcomes.
- The CA-125 elimination rate constant (KELIM-B) has shown prognostic value in previous studies.
Purpose Of The Study
- To evaluate if a joint semi-mechanistic model integrating CA-125 kinetics and tumor size improves prognostic accuracy compared to CA-125 kinetics alone.
- To assess the prognostic value of KELIM-B and a joint model parameter (KELIM-joint) for progression-free survival (PFS) and overall survival (OS).
Main Methods
- Two kinetic-pharmacodynamic models were developed: a CA-125 longitudinal kinetics model and a joint model incorporating tumor size.
- Data from 74 patients in the BOLD phase II trial (recurrent advanced ovarian cancer treated with bevacizumab, olaparib, durvalumab) were analyzed.
- Univariate and multivariate analyses assessed the prognostic value of KELIM-B and KELIM-joint for PFS and OS.
Main Results
- Both CA-125 kinetics and the joint model were feasible to develop with adequate quality.
- The joint model's prognostic value (KELIM-joint) was not clinically different from CA-125 kinetics alone (KELIM-B) for PFS and OS.
- Interactions between tumor size and CA-125 kinetics were assessable in the joint model, but did not offer sufficient prognostic improvement.
Conclusions
- The complexity of a joint model integrating tumor size and CA-125 kinetics is not justified by a significant improvement in prognostic value.
- Assessing early longitudinal CA-125 kinetics alone remains the most pragmatic and effective strategy for prognostic assessment in this setting.
- This finding supports the continued use of CA-125 kinetics as a companion test for guiding treatment development in recurrent ovarian cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...